Work

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab

Year: 2020

Type: article

Abstract: Pyoderma gangrenosum is an inflammatory condition characterized by the presence of painful and necrotic ulcerations with a neutrophil-rich infiltrate. Although its pathogenesis is not completely understood, pyoderma gangrenosum has been associated with autoimmune disorders, such as inflammatory bowel disease. Drug-induced pyoderma gangrenosum has also been reported in the literature, particularly in relation to new targeted therapies including infliximab, adalimumab, and rituximab.1 Herein, we present a novel case of pyoderma gangrenosum induced by secukinumab, an anti-interleukin (IL) 17A antibody in a patient with psoriasis.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2020.06.011

Authors: Amy J. Petty, Melodi J. Whitley, Alexandra Balaban, Kenneth Ellington, Anne L. Marano

Institution: Duke University

Language: English

Topic: Autoimmune and Inflammatory Disorders

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $600